Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy provides effective treatment for large B-cell lymphoma (LBCL). Cost-utility analyses examining and comparing the value of these treatments require health state utilities representing key characteristics to differentiate among therapies. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Timothy A., Matza, Louis S., Jun, Monika P., Garcia, Jacob, Powers, Annette, Maloney, David G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043043/
https://www.ncbi.nlm.nih.gov/pubmed/35129829
http://dx.doi.org/10.1007/s41669-021-00316-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043043/
https://www.ncbi.nlm.nih.gov/pubmed/35129829
http://dx.doi.org/10.1007/s41669-021-00316-0

Ejemplares similares